Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Brandon Lehr

Physician Assistant Bradenton, FL Physician Assistant

NPI 1558992875 CMS profile 10538440

4805 26Th St W, Bradenton, FL 34207

Open in the dashboard

General payments

$6,087

295 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Brandon Lehr of Bradenton, FL is reported in the CMS Open Payments database as having received $6,087 across 295 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,300 46
2024 General $1,143 59
2023 General $1,020 47
2022 General $646 35
2021 General $1,977 108

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Brandon Lehr
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Brandon Lehr were reported at $1,300. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Brandon Lehr Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $1,977 $132 $37–$438 $132
2022 $646 $155 $48–$522 $149
2023 $1,020 $167 $52–$557 $160
2024 $1,143 $178 $55–$600 $164
2025 $1,300 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Gilead Sciences, Inc. $2,210 104 payments
  2. ViiV Healthcare Company $1,917 89 payments
  3. AbbVie, Inc. $427 24 payments
  4. Merck Sharp & Dohme Corporation $321 19 payments
  5. Janssen Biotech, Inc. $290 16 payments
  6. Theratechnologies Inc. $240 10 payments
  7. Paratek Pharmaceuticals, Inc. $102 6 payments
  8. Janssen Products, LP $99 1 payment
  9. Exact Sciences Corporation $85 3 payments
  10. Insmed, Inc. $78 5 payments
  11. Other $319 18 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $5,917 290 payments
  2. Education $169 5 payments
Products named General payments · program years 2021–2025
  1. DOVATO $1,549 68 payments
  2. SYMTUZA $389 17 payments
  3. Biktarvy $308 6 payments
  4. DELSTRIGO $307 18 payments
  5. MAVYRET $298 16 payments
  6. PIFELTRO $270 16 payments
  7. CABENUVA $248 16 payments
  8. ISENTRESS $231 14 payments
  9. DIFICID $226 13 payments
  10. TROGARZO $198 8 payments
  11. Other $1,128 60 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 121 drugs

Part D claims

5,704

Median for Physician Assistant: 241

Drug cost

$5,083,569

Median for Physician Assistant: $4,110

Branded share of claims

42.6%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Biktarvy Bictegrav/Emtricit/Tenofov Ala Brand 556 $2,227,490
Dovato Dolutegravir Sodium/Lamivudine Brand 137 $413,472
Genvoya Elviteg/Cob/Emtri/Tenof Alafen Brand 77 $320,135
Epclusa Sofosbuvir/Velpatasvir Brand 12 $284,568
Symtuza Darunavir/Cob/Emtri/Tenof Alaf Brand 47 $250,504
Rukobia Fostemsavir Tromethamine Brand 26 $230,787
Tivicay Dolutegravir Sodium Brand 87 $198,962
Triumeq Abacavir/Dolutegravir/Lamivudi Brand 47 $180,572
Odefsey Emtricitab/Rilpiviri/Tenof Ala Brand 50 $178,146
Descovy Emtricitabine/Tenofov Alafenam Brand 64 $144,334

The 10 drugs with the highest cost, of 121 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 10 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DOVATO
  • ViiV Healthcare Company $377
$377 137 —
Biktarvy
  • Gilead Sciences, Inc. $125
$125 556 —
CABENUVA
  • ViiV Healthcare Company $45
$45 — —
APRETUDE
  • ViiV Healthcare Company $41
$41 — —
EGRIFTA
  • Theratechnologies Inc. $36
$36 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 10 in the dashboard with a free account

Records

295 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record